Things for Merck (MRK) are looking really good after it had obtained its latest win for Keytruda. It reported positive news from its phase 3 study known as KEYNOTE-042, which treated patients with front-line non-small cell lung cancer (NSCLC). This piece of news will allow Merck to potentially target this market without the use of chemotherapy, Keytruda treatment alone as a monotherapy, which is a huge positive. A trial from Bristol-Myers Squibb(BMY) with Opdivo failed to be successful in the front-line NSCLC setting as a monotherapy. This bodes well for Merck and its future of Keytruda sales.
